Ethiopia Ebola Odds Fall 18 Points as DRC Cases Top 200

---

Ethiopia's Ebola Risk Drops 18 Points in Three Days, Even as DRC Cases Double

On prediction markets tracking which countries will report an Ebola case in 2026, Ethiopia's implied probability collapsed from 54% to 36% over three days, even as the underlying outbreak worsened. The World Health Organization confirmed on September 16 that weekly Ebola cases in North Kivu nearly doubled, surging from roughly 100 to more than 200 in two weeks. Three days later, Congo launched a vaccination campaign targeting 20,000 health workers in Bunia, the epicenter of the outbreak. The market's response: sell Ethiopia's risk, hard.

The contract now sits one percentage point above its all-time low of 35%. That 18-point drop is the kind of move that usually accompanies a confirmed containment event or a definitive policy action. Neither has occurred here. The market appears to be front-running a thesis: vaccination momentum will prevent cross-border spread, regardless of what the raw case data says.

But the two platforms pricing this outcome disagree sharply. Kalshi has Ethiopia at 22%. Polymarket prices it at 50%. That 28-point spread between venues is unusually wide and undermines any clean read of market consensus. Before interpreting the drop, it is worth understanding just how bad the underlying outbreak has become.

---

Is the DRC Ebola Outbreak Getting Worse in 2026? The Numbers Behind the Surge

The answer is unambiguous: yes. Weekly confirmed cases in North Kivu crossed 200, a pace that places this among the fastest-growing Ebola outbreaks in history. The outbreak has already spread to at least two new health zones, totaling more than 600 cumulative cases. Geographic expansion within DRC raises the probability of eventual cross-border transmission.

The circulating pathogen, the Bundibugyo strain, complicates every containment playbook. There is no licensed vaccine or treatment specifically designed for Bundibugyo. The Ervebo vaccine being deployed in Bunia was developed against the Zaire strain. Cross-protective efficacy against Bundibugyo remains unproven in large-scale field conditions, though experimental data and the WHO's decision to proceed suggest some basis for optimism.

Ethiopia does not share a direct border with the DRC. But the broader East and Central African disease corridor, running through Uganda, South Sudan, and Kenya, has historically served as a transmission pathway during prior outbreaks. Uganda, which sits between the DRC and Ethiopia, experienced Ebola spillovers as recently as 2022. If a case reaches Uganda, Ethiopia's risk profile changes overnight.

---

Why Ethiopia's Chances Are Falling: Vaccination Momentum and Containment Signals

The 18-point drop is best explained as markets pricing process over outcome. The September 19 vaccination launch in Bunia represents the first large-scale containment intervention of this outbreak. Historical patterns in prediction markets show that odds of geographic spread tend to decline when vaccination campaigns begin, even before those campaigns produce measurable epidemiological results. The market is rewarding intent and infrastructure, not confirmed efficacy.

Prediction-market view

Live prices, venue by venue

Compare the latest YES price at each venue. Check market rules, liquidity, and fees before trading.

Ethiopia

Consensus YES price across 1 venues

51%average

PolymarketBest YES price91¢

Central African Republic

Consensus YES price across 1 venues

38%average

KalshiBest YES price40¢

Tanzania

Consensus YES price across 1 venues

16%average

KalshiBest YES price17¢

Zambia

Consensus YES price across 1 venues

11%average

KalshiBest YES price12¢

Three factors likely contributed to the drop. First, the 20,000-worker vaccination target signals that the WHO and Congolese health authorities have identified and are actively protecting the highest-risk transmission nodes: frontline health workers. Second, Ethiopia's own surveillance posture, including border screening protocols established during prior East African outbreaks, reduces the probability of undetected importation. Third, with roughly 100 days remaining until the contract's January 1, 2027 resolution date, the market may be compressing the time window in which a DRC-to-Ethiopia chain of transmission could realistically occur.

The 28-point spread between Kalshi (22%) and Polymarket (50%) deserves direct attention. Kalshi's lower price suggests its participant base is more confident in containment. Polymarket's higher price may reflect a different information mix, or simply thinner positioning on this specific outcome. Without confirmed volume data, it is impossible to say which venue carries more informed flow. The spread itself is the story: there is no market consensus on Ethiopia's Ebola risk. There are two very different bets being placed by two very different pools of participants.

---

The Case Against Ethiopia's Falling Chances: Why This Market Could Be Mispricing Ebola Risk

The strongest argument for higher Ethiopia risk rests on three pillars, each grounded in the current data.

First, the Ervebo vaccine being deployed has no proven efficacy against Bundibugyo. The market appears to be treating the vaccination campaign as a generic containment signal, but the strain mismatch is not a minor footnote. If cross-protective immunity proves weak, the campaign buys time without solving the transmission problem. A 200-case-per-week outbreak with an ineffective vaccine is worse than a 100-case-per-week outbreak with no vaccine, because false security may reduce behavioral precautions.

Second, the outbreak is still expanding geographically within DRC. Each new health zone reached increases the surface area for potential cross-border transmission. The conflict-affected eastern DRC remains one of the hardest places on earth to conduct disease surveillance, meaning official case counts almost certainly understate actual transmission.

Third, the 100-day window before resolution is not short. The 2014 West African Ebola outbreak went from a localized Guinean event to a three-country crisis in roughly 90 days. Ethiopia's distance from DRC is a buffer, not a wall. A single infected traveler transiting through Uganda or South Sudan could trigger a confirmed Ethiopian case within weeks of arrival.

Polymarket's 50% price may more accurately reflect these tail risks than Kalshi's 22%. The blended 36% sits in an uncomfortable middle ground: too low if the vaccination campaign fails, too high if it succeeds and DRC's case curve bends within the next month. Live pricing across all country outcomes is available on the Ethiopia Ebola prediction market page.

The market has made a directional bet on containment optimism. The question is whether a vaccination campaign using a mismatched vaccine against a doubling outbreak justifies an 18-point repricing. The case count says no. The market, for now, says yes.